The study is researching an experimental drug called odronextamab. The study is for patients with previously untreated follicular lymphoma (a type of non-Hodgkin lymphoma). In this study, we want to find out more about how safe and tolerable the study drug is. We will also compare how well the study drug orks compared to rituximab and chemotherapy (the current standard of care for NHL).
If you decide to take part, you will receive course of either the study drug (odronextamab) or the standard of care chemotherapy and rituximab once every 3 weeks for 6 weeks (18 weeks total). You will then receive maintenance treatment, consisting of odronextamab or rituximab for up to a year. You also will be asked to complete questionnaires and have some tests like a CT, PET scan, and an MRI. We also may take biopsies or your lymph nodes or bone marrow. Once the study treatment is over, you will return for follow up visits to UNC every 3 months until either the study is completed, you start another treatment, or decide to withdraw from the study.
Study drug is provided by the sponsor. Optional travel Reimbursement and a 75$ stipend per treatment visit is available.
Lineberger Comprehensive Cancer Center
NC Cancer Hospital (Basnight)
UNC Hospitals / UNC Medical Center
101 Manning Dr, Chapel Hill, NC 27514, USA
Natalie Grover
LCCC - Clinical Trials
Clinical or Medical
Interventional
Cancer (Lymphoma)
23-1232